Andrea Alemany1, Pere Millat-Martinez2, Dan Ouchi3, Marc Corbacho-Monné3, Antoni E Bordoy4, Cristina Esteban4, Águeda Hernández4, Cristina Casañ4, Victoria Gonzalez4, Gèlia Costes3, Mar Capdevila-Jáuregui3, Pamela Torrano-Soler3, Alba San José3, Jordi Ara5, Núria Prat6, Bonaventura Clotet7, Quique Bassat8, Montserrat Gimenez4, Ignacio Blanco5, Bàrbara Baro9, Oriol Mitjà10. 1. Fight AIDS and Infectious Diseases Foundation, Badalona, Spain; Hospital Universitari Germans Trias i Pujol, Barcelona Institute for Global Health, Rosselló, 132, Badalona 08036, Spain. 2. ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain. 3. Fight AIDS and Infectious Diseases Foundation, Badalona, Spain. 4. Hospital Universitari Germans Trias i Pujol, Barcelona Institute for Global Health, Rosselló, 132, Badalona 08036, Spain. 5. Hospital Universitari Germans Trias i Pujol, Barcelona Institute for Global Health, Rosselló, 132, Badalona 08036, Spain; Gerència Territorial Metropolitana Nord, Institut Català de la Salut, Barcelona, Spain. 6. Gerència Territorial Metropolitana Nord, Institut Català de la Salut, Barcelona, Spain. 7. Fight AIDS and Infectious Diseases Foundation, Badalona, Spain; Hospital Universitari Germans Trias i Pujol, Barcelona Institute for Global Health, Rosselló, 132, Badalona 08036, Spain; Universitat de Vic-Universitat Central de Catalunya (UVIC-UCC), Vic, Spain. 8. ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique; ICREA, Pg. Lluís Companys 23, Barcelona 08010, Spain; Pediatrics Department, Hospital Sant Joan de Déu (University of Barcelona), Barcelona, Spain; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. 9. ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain. Electronic address: barbara.baro@isglobal.org. 10. Fight AIDS and Infectious Diseases Foundation, Badalona, Spain; Hospital Universitari Germans Trias i Pujol, Barcelona Institute for Global Health, Rosselló, 132, Badalona 08036, Spain; Lihir Medical Centre, International SOS Clinic, Lihir Island, Papua New Guinea.
The use of self-collected specimens for the screening of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has gained interest as they may facilitate massive screening campaigns. Various authors have reported that mid-nasal swabs
,
and saliva3, 4, 5, 6 are reliable specimens, alternative to nasopharyngeal swabs, to detect SARS-CoV-2 infections by RT-qPCR, irrespective of the age group tested. Despite drawing consistent conclusions, studies reported heterogeneous results regarding the performance of each type of sample, particularly sensitivity, which strongly depends on the viral load distribution of the investigated population and sample collection protocols. In the case of saliva, discrepancies regarding sensitivity might be even higher due to optimized protocols for RNA extraction adapted to the rheological properties of saliva.
,
Therefore, there is a need for better characterizing-also from a quantitative perspective-the performance of self-collected specimens before using them as an alternative to nasopharyngeal swabs for SARS-CoV-2 screening.In the context of a randomized clinical trial targeting mild COVID-19 patients (NCT04621123), we enrolled 130 adults in a sub-study to directly compare self-collected mid-nasal swabs and saliva specimens for SARS-CoV-2 detection by RT-qPCR, using nasopharyngeal swabs collected by the study nurses as a reference. Included patients had a mean age of 59 (SD 8.5) and a median of 4 days (95% IC 3–5) from symptoms onset; 43.2% were females. Patients received written instructions to self-collect a mid-nasal swab from both nostrils by introducing the swab 2,3 cm and rotating during 5 s, and 1 mL of saliva by spitting inside the funnel of a collection device (DANASALIVA™ sample collection kit). Participants were advised to avoid eating, drinking, smoking, and brushing their teeth within 30 min prior to sample collection. Self-collection was done in the presence of a study nurse, although they did not intervene during the collection process. Next, the study nurse collected a nasopharyngeal swab from both nostrils. Swab specimens were placed into sterile tubes containing viral transport media (DeltaSwab Virus). Saliva was mixed with 1 mL of saliva preservation solution in the collection device, following manufacturer's instructions. No additional pre-treatment step potentially increasing saliva sensitivity
,
was used before RNA extraction. All three specimens were transported to the Microbiology laboratory of Hospital Germans Trias i Pujol and stored at 2–8 °C for up to 24 h before RT-qPCR. Paired samples were collected at baseline and 7 days after enrollment.RNA was extracted using the STAR Mag reagent (Seegen) for the Microlab Starlet IV or Nimbus platforms (Hamilton life Science Robotics, USA), according to the manufacturer's instructions. PCR amplification was conducted according to the recommendations of the 2019-nCoV RT-qPCR Diagnostic Panel of the Centers for Disease Control and Prevention (CDC) using the Allplex™ 2019-nCoV assay (Seegene, South Korea) on the CFX96 (Bio-Rad, USA) according to manufacturer's instruction.The three paired samples were successfully obtained in 129 of 130 patients, with 120 (92.3%) showing a positive nasopharyngeal swab at baseline. Compared to nasopharyngeal swabs, self-collected mid-nasal swabs and saliva samples showed a sensitivity of 99.2% (119/120) and 90.0% (108/120), respectively. This result is in line with a recently published head-to-head comparison, which included 38 positive COVID-19 cases. Of the nine participants with nasopharyngeal swabs testing negative, two had a positive saliva specimen and one a positive nasal swab. Given the successful internal PCR controls and the high cycle threshold (Ct) values (all above 30; days from symptom onset ranging from 4 to 6), we presume these patients were approaching the recovered state, with viral loads close to negativity.In addition to the qualitative and semi-quantitative analyses conducted in previous works, we estimated the viral load of each specimen and correlated the values observed in self-collected samples with those of nasopharyngeal swabs. The RT-qPCR Ct of positive specimens was, in mean (SD), 20.64 (3.43) for nasopharyngeal swabs, 22.90 (4.60) for mid-nasal swabs, and 29.56 (4.50) for saliva specimens (Fig. 1
A). The Pearson lineal correlation between viral loads obtained from nasopharyngeal swabs and self-collected specimens revealed a strong correlation for mid-nasal swabs (R = 0.88; p < 0.001) and a fair correlation for saliva specimens (R = 0.50; p < 0.001) (Fig. 2
A).
Fig. 1
Distribution of RT-qPCR cycle threshold (Ct) of nasopharyngeal swabs, nasal swabs, and saliva specimens collected at baseline (A) and day 7 (B). Cts correspond to the viral RNA-dependent RNA polymerase (RdRP) gene.
Fig. 2
Correlation of the viral load (VL) of nasopharyngeal swabs with that of nasal swabs and saliva specimens at baseline (A) and day 7 (B). Viral loads were estimated using a calibration line obtained with serial dilutions of SARS-CoV-2 control RNA, run in parallel to a set of samples covering all thermal cycles used in the analysis. Negative samples (in red) were assigned to a Ct of 40 (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.).
Distribution of RT-qPCR cycle threshold (Ct) of nasopharyngeal swabs, nasal swabs, and saliva specimens collected at baseline (A) and day 7 (B). Cts correspond to the viral RNA-dependent RNA polymerase (RdRP) gene.Correlation of the viral load (VL) of nasopharyngeal swabs with that of nasal swabs and saliva specimens at baseline (A) and day 7 (B). Viral loads were estimated using a calibration line obtained with serial dilutions of SARS-CoV-2 control RNA, run in parallel to a set of samples covering all thermal cycles used in the analysis. Negative samples (in red) were assigned to a Ct of 40 (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.).Of the 120 nasopharyngeal swabs obtained on day 7 (i.e., a mean of 11 days [range 10–12] from symptom onset), 28 tested negative and 92 positive. Mean Ct values were 31.85 (4.63), 33.95 (4.75), and 36.69 (4.42) for positive nasopharyngeal, mid-nasal and saliva specimens, respectively (Fig. 1B). As expected, the mean viral load was lower at day 7 than at baseline (p < 0.001). Compared to nasopharyngeal swabs, self-collected mid-nasal swabs and saliva specimens showed a sensitivity of 72.8% (67/92) and 42.4% (39/92), respectively, suggesting poorer performance at low viral loads. Of note, most negative self-collected samples with a positive paired nasopharyngeal swab yielded Ct values above 30 (92% and 52% of the nasal and saliva specimens, respectively). The viral load correlation with nasopharyngeal swab was poor for saliva specimens (R = 0.3; p = 0.003) and moderate for mid-nasal swabs (R = 0.67; p < 0.001) (Fig. 2B).In summary, our findings show that self-collected mid-nasal swabs have better performance than saliva for detecting SARS-CoV-2 when compared with the gold-standard nasopharyngeal swabs. Of note, the sensitivity of saliva was remarkably high in samples with higher viral load, despite not using any of the RNA extraction protocols adapted to the rheological properties of this sample. Considering that respiratory specimens with Ct above 33,34 are unlikely to be contagious, our finding indicates that saliva would be sensitive enough to identify individuals at risk of transmission. Furthermore, the enhanced sensitivity achieved with adapted protocols for RNA extraction from saliva suggests that this might be the sample of choice for systematic screenings in settings in which a specific laboratory pathway can be implemented (e.g., school children).Taken together, the existing literature and the results provided in our analysis encourage the use of self-collected specimens (mid-nasal when possible and saliva in vulnerable populations such as children) for massive screenings of SARS-CoV-2.
Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Authors: Vic Veguilla; Ashley L Fowlkes; Adam Bissonnette; Shawn Beitel; Manjusha Gaglani; Christina A Porucznik; Melissa S Stockwell; Harmony L Tyner; Allison L Naleway; Sarang K Yoon; Alberto J Caban-Martinez; Meredith G Wesley; Jazmin Duque; Zuha Jeddy; Joseph B Stanford; Michael Daugherty; Ashton Dixon; Jefferey L Burgess; Marilyn Odean; Holly C Groom; Andrew L Phillips; Natasha Schaefer-Solle; Peenaz Mistry; Melissa A Rolfes; Mark Thompson; Fatimah S Dawood; Jennifer Meece Journal: Microbiol Spectr Date: 2022-06-06